However, immunotherapy based on PD‐L1 and CTLA‐4 immune checkpoint inhibitors, has shown limited effectiveness in pancreatic cancer patients, with only 3.1% achieving objective responses.[3] This is mainly because pancreatic cancer is mostly considered as a “cold” tumor with limited immune cell infiltration. The gene discussed is CTLA4; the disease is familial pancreatic carcinoma.